These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6868021)

  • 1. Further studies of the turnover of dog antithrombin III. Study of 131I-labelled antithrombin protease complexes.
    Leonard B; Bies R; Carlson T; Reeve EB
    Thromb Res; 1983 Apr; 30(2):165-77. PubMed ID: 6868021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal antithrombin III with defective serine protease binding (antithrombin III "Denver").
    Sambrano JE; Jacobson LJ; Reeve EB; Manco-Johnson MJ; Hathaway WE
    J Clin Invest; 1986 Mar; 77(3):887-93. PubMed ID: 3512602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heparin-catalyzed inhibitor/protease reactions: kinetic evidence for a common mechanism of action of heparin.
    Griffith MJ
    Proc Natl Acad Sci U S A; 1983 Sep; 80(18):5460-4. PubMed ID: 6577437
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and functional study of antithrombin III in newborn infants.
    McDonald MM; Hathaway WE; Reeve EB; Leonard BD
    Thromb Haemost; 1982 Feb; 47(1):56-8. PubMed ID: 7071806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of heparin fractions of different affinities to antithrombin III and thrombin on the inactivation of thrombin and factor Xa by antithrombin III.
    Cerskus AL; Birchall KJ; Ofosu FA; Hirsh J; Blajchman MA
    Can J Biochem Cell Biol; 1984 Oct; 62(10):975-83. PubMed ID: 6509363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antithrombin-III-Hamilton, Ala 382 to Thr: an antithrombin-III variant that acts as a substrate but not an inhibitor of alpha-thrombin and factor Xa.
    Austin RC; Rachubinski RA; Ofosu FA; Blajchman MA
    Blood; 1991 May; 77(10):2185-9. PubMed ID: 2029579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic analysis of various heparin fractions and heparin substitutes in the thrombin inhibition reaction.
    Pletcher CH; Cunningham M; Nelsestuen GL
    Biochim Biophys Acta; 1985 Jan; 838(1):106-13. PubMed ID: 2578296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the biological activity of antithrombin III in patients with hepatic cirrhosis.
    Matsuo T; Matsuo C; Matsuo O
    Clin Chim Acta; 1984 Jul; 140(2):125-32. PubMed ID: 6467606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinction of two pathologic antithrombin III molecules: antithrombin III "Aalborg' and antithrombin III "Budapest'.
    Sørensen PJ; Sas G; Petó I; Blaskó G; Kremmer T; Samu A
    Thromb Res; 1982 May; 26(3):211-9. PubMed ID: 7112514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of factor IXa in vitro in human and mouse plasma and in vivo in the mouse. Role of the endothelium and the plasma proteinase inhibitors.
    Fuchs HE; Trapp HG; Griffith MJ; Roberts HR; Pizzo SV
    J Clin Invest; 1984 Jun; 73(6):1696-703. PubMed ID: 6202716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of an abnormal antithrombin (Milano 2) with defective thrombin binding.
    Tripodi A; Krachmalnicoff A; Mannucci PM
    Thromb Haemost; 1986 Dec; 56(3):349-52. PubMed ID: 3563966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparin.
    Lane DA; Flynn A; Ireland H; Erdjument H; Samson D; Howarth D; Thompson E
    Br J Haematol; 1987 Apr; 65(4):451-6. PubMed ID: 3580302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism of antithrombin III (heparin cofactor) in man: effects of venous thrombosis and of heparin administration.
    Collen D; Schetz J; de Cock F; Holmer E; Verstraete M
    Eur J Clin Invest; 1977 Feb; 7(1):27-35. PubMed ID: 65284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crossed immunoelectrophoresis as applied to studies on complex formation. The binding of heparin to antithrombin III and the antithrombin III--thrombin complex.
    Andersson LO; Engman L; Henningsson E
    J Immunol Methods; 1977; 14(3-4):271-81. PubMed ID: 557071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification and characterization of hereditary abnormal antithrombin III with impaired thrombin binding.
    Jørgensen M; Petersen LC; Thorsen S
    J Lab Clin Med; 1984 Aug; 104(2):245-56. PubMed ID: 6747440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homozygous variant of antithrombin III that lacks affinity for heparin, AT III Kumamoto.
    Okajima K; Ueyama H; Hashimoto Y; Sasaki Y; Matsumoto K; Okabe H; Inoue M; Araki S; Takatsuki K
    Thromb Haemost; 1989 Feb; 61(1):20-4. PubMed ID: 2749590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro characterization of antithrombin III concentrates--a single-blind study.
    Hellstern P; Moberg U; Ekblad M; Anders CU; Faller B; Müller S
    Haemostasis; 1995; 25(4):193-201. PubMed ID: 7557658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of hyperglycaemia-induced alterations of antithrombin III and factor X activation in the thrombin hyperactivity of diabetes mellitus.
    Ceriello A; Quatraro A; Marchi E; Barbanti M; Dello Russo P; Lefebvre P; Giugliano D
    Diabet Med; 1990 May; 7(4):343-8. PubMed ID: 2140088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Covalent complexes between low molecular weight heparin fragments and antithrombin III - inhibition kinetics and turnover parameters.
    Hoylaerts M; Holmer E; de Mol M; Collen D
    Thromb Haemost; 1983 Apr; 49(2):109-15. PubMed ID: 6868006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of thrombin and endotoxin on the in vivo metabolism of antithrombin III (AT III) in dogs.
    Tanaka H; Kobayashi N; Maekawa T
    Thromb Res; 1985 Nov; 40(3):291-306. PubMed ID: 4082111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.